Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: dipyridamole | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 13089
Sealed predictions
- SLC29A1 in dopamine neurons, braak-0.58 (p 0.099) → -0.31 (p 0.422)receipt 13096
Swarm cases
receipt 13096: SLC29A1 in dopamine neurons, braak
- power
- full sample -0.54 (p 0.021, n 18), 95% CI -0.80 to -0.10. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.48 (p 0.042, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.62 (p 0.0057, n 18). not the mix.
- skeptic
- leave-one-out range -0.65 to -0.47, sign flips 0; without severely affected donors -0.54 (p 0.021, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SLC29A1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts